Objective: To evaluate the effect of topical oxygen therapy on cytokines and healing in patients with diabetic foot ulcers.
Methods: This prospective cohort study evaluated 23 patients with diabetic foot ulcers that received Continuous Diffusion of Oxygen treatment over four visits. Wound size, hyperspectral imaging, transcutaneous oxygen measurements, cytokines (CXCL8, PDGF, IGF-1β, TGF-β, IL6, VEGF, and TNF-α), and bacterial cultures were obtained weekly. We used analysis of variance to test for differences in continuous variables. For this pilot study we used an α = 0.10.
Results: The results of this study show there is no significant difference between transcutaneous oxygen on plantar and dorsal foot (53.91 ± 13.97) and (57.81 ± 13.59), oxygenated or deoxygenated hemoglobin (Hgb) (64.50 ± 33.94) and (61.86 ± 23.80), or quantitative cultures at the time points. 60% of people had percent wound area reduction There is a significant difference between the levels of TGF-β and TNF-α between visits 1 and 2, p values 0.006 and 0.01 respectively. For VEGF p=0.00508 and IL6 p=0.11. The results were analyzed by patients with percent wound area reduction >50% (healers N=12, 52%) and non-healers (N=11, 48%). The median concentrations of cytokines between healers and non-healers for the four visits are shown in Figure 1.
L.A. Lavery: Advisory Panel; Self; Acelity, Bayer AG. Consultant; Self; Boehringer Ingelheim International GmbH. Research Support; Self; AstraZeneca, Cardinal Health, EO2 Concepts, Integra LifeSciences, MedImmune, Smith & Nephew. A.L. Killeen: None. J. La Fontaine: None. Y. Akgul: None. P. Crisologo: None.
EO2 Concepts (19069)
